Skip to main content
Retour
Watch Compare

Theriva Biologics, Inc.

Qualité des données : 83%
TOVX
NYSE Manufacturing Chemicals
0,24 €
▼ 0,06 € (-19,19%)
Cap. Boursière: 11,01 M
Prix
0,24 €
Cap. Boursière
11,01 M
Fourchette du Jour
0,24 € — 0,28 €
Fourchette 52 Semaines
0,16 € — 1,50 €
Volume
4 767 400
Ouverture 0,28 €
Moyenne 50J / 200J
0,20 €
23,08% above
Moyenne 50J / 200J
0,31 €
23,69% below

Quick Summary

Points Clés

Negative free cash flow of -16,70 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-273,48%
En dessous de la moyenne du secteur (-53,41%)
ROIC-87,82%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,90
Interest Coverage-394,28

Valorisation

PE (TTM)
-0,46
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio1,63
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,5 -1,5
P/B 1,6 1,6
ROE % -273,5 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -23,74 M
ROE -273,48% ROA -71,22%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -16,70 M
ROIC -87,82% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,90
Interest Coverage -394,28 Asset Turnover N/A
Working Capital -1,10 M Tangible Book Value -12,88 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,46 Forward P/E N/A
P/B Ratio 1,63 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -151,66%
Market Cap 11,01 M Enterprise Value 3,49 M
Per Share
EPS (Diluted TTM) -2,08 Revenue / Share N/A
FCF / Share -0,36 OCF / Share -0,36
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 70,37%
SBC-Adj. FCF -17,38 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -23,74 M -25,65 M -18,35 M -19,69 M -14,27 M
EPS (Diluted) -2,08 -19,03 -1,14 -1,31 -0,19
Gross Profit — — — — —
Operating Income -24,05 M -26,35 M -21,43 M -21,58 M -14,27 M
EBITDA — — — — —
R&D Expenses 8,60 M 12,03 M 14,31 M 11,72 M 7,80 M
SG&A Expenses — — — — —
D&A 108 000,0 137 000,0 135 000,0 85 000,0 87 000,0
Interest Expense 61 000,0 — — — —
Income Tax — 0,0 -1,64 M -1,43 M 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 38,24 M 35,35 M 55,22 M 71,86 M 70,37 M
Total Liabilities 22,86 M 16,29 M 15,52 M 17,30 M 4,96 M
Shareholders' Equity 15,38 M 19,07 M 36,96 M 56,39 M 65,41 M
Total Debt 1,67 M 92 000,0 225 000,0 278 000,0 —
Cash & Equivalents 13,06 M 11,61 M 23,18 M 41,79 M 67,33 M
Current Assets 17,47 M 16,28 M 27,40 M 45,52 M 68,86 M
Current Liabilities 10,01 M 7,59 M 6,74 M 7,06 M 3,55 M